Ciclomex CD

Quick links to important sections

Ciclomex CD

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciclomex CD

Property Description
Active Ingredients Ethinyl Estradiol, Gestodene
Form Oral Tablet (Monophasic)
Pharmacological Class Hormonal Contraceptive (Estrogen-Progestin Combination)
Common Use Prevention of pregnancy
Origin Synthetic

What Type of Medicine is Ciclomex CD?

Ciclomex CD is classified as a combined oral contraceptive (COC), which is a prescription-only medicine (Rx) belonging to the broader hormonal contraceptive pharmacological class. The preparation is a synthetic drug entity delivered as an oral tablet intended for oral administration. The components of Ciclomex CD combine to suppress reproductive signaling pathways, a method clinically recognized for high contraceptive reliability.


Ciclomex CD: Active Ingredients and Composition

The preparation is a combination product containing two distinct active substances: Ethinyl Estradiol and Gestodene. Ethinyl Estradiol is a synthesized estrogen, and Gestodene is a synthetic third-generation progestogen. This combination places Ciclomex CD among the newer COCs. As a monophasic oral tablet, Ciclomex CD maintains the same fixed concentration of both these hormones in every active tablet within the cycle, providing a consistent hormonal input.


What is the Primary Purpose of Ciclomex CD?

The primary purpose of Ciclomex CD is to provide effective contraception for women of reproductive age, aiming to reliably minimize the possibility of conception. This effect is achieved through the combined action of the two synthetic hormones, which prevent an egg from being released (inhibition of ovulation) and also alter the cervical mucus, creating an environment unfavorable to sperm movement. This robust, layered mechanism ensures dependable pregnancy prevention.

What side effects are possible with Ciclomex CD?

Possible Side Effects

Ciclomex CD (clomiphene citrate) is generally well-tolerated, but some side effects may occur. Most side effects are mild and usually resolve after the course of treatment is finished. Consult your healthcare provider if any side effects are severe or persistent.

Classification Common Side Effects (Affecting up to 10% of users)
General Hot flashes (vasomotor flushes)
Gastrointestinal Nausea, vomiting, abdominal or pelvic discomfort, bloating
Neurological Headaches
Reproductive Breast discomfort, abnormal uterine bleeding or spotting
Vision Blurred vision or other visual disturbances (e.g., seeing spots or flashes)

Serious Warnings and Precautions

Ovarian Hyperstimulation Syndrome (OHSS): This is a rare but potentially serious condition that involves the enlargement of the ovaries. Symptoms may include severe pelvic pain, significant abdominal swelling or bloating, rapid weight gain, shortness of breath, and reduced urination. If these symptoms occur, stop taking Ciclomex CD immediately and contact your doctor for urgent medical evaluation.

Visual Symptoms: Changes in vision, such as blurred vision or seeing spots/flashes (scintillating scotomata), are uncommon but require immediate attention. Visual disturbances may worsen with increased dosage or prolonged use. If you experience any visual changes, discontinue the medication and seek an eye examination promptly.

Contraindications: Ciclomex CD should not be used if you are pregnant, have uninvestigated abnormal vaginal bleeding, ovarian cysts (other than those related to Polycystic Ovary Syndrome), liver disease, or certain hormone-dependent tumors. Your doctor will perform a pelvic examination and blood tests before starting each treatment cycle. Extended use beyond a total of six cycles is not recommended due to a potential, though unconfirmed, increase in the risk of ovarian cancer.

Overdose and Emergency Response

Ciclomex CD Overdose and When to Seek Help

This section describes the officially documented manifestations and required emergency actions in the event of an overdose, as stated in government regulatory prescribing information.


Documented Overdose Presentations

The acute ingestion of a large quantity of Ciclomex CD is generally classified in regulatory documents as not likely to be life-threatening. Documented clinical manifestations primarily involve gastrointestinal effects such as nausea and vomiting. A distinct, delayed manifestation is withdrawal bleeding (vaginal bleeding), which is expected to occur a few days following the acute ingestion. Other possible acute manifestations include headache, drowsiness, and breast tenderness. The official profile consistently states that no specific antidote is known for this combination of hormones.


Required Emergency Actions and Management

In all cases of suspected or confirmed overdose, the official regulatory instruction is to seek medical help right away and contact a national Poison Control Center for immediate guidance. The need for professional attention is emphasized, especially regarding accidental pediatric ingestion, which is subject to specific regulatory consideration.

Treatment is explicitly limited to symptomatic and supportive measures. This management approach requires medical monitoring of vital signs (temperature, pulse, blood pressure) and may involve performing blood and urine tests. Regulatory documents reinforce that this supportive protocol is necessary due to the absence of a specific reversal agent.

Therapeutic Uses of Ciclomex CD

The therapeutic scope of Ciclomex CD generally extends beyond its primary function, applied across domains where additional symptomatic support is needed. The medication is relevant in contexts marked by increased discomfort or tension supporting patients with distinct gynecological and dermatological needs.

The primary purpose is applied to help manage reliable, reversible reproductive planning. Additionally, Ciclomex CD is commonly used to help with symptomatic relief in conditions involving severe menstrual cramps (dysmenorrhea), excessive menstrual blood loss (menorrhagia), pronounced symptoms of hormonal acne and hirsutism, and the disruptive emotional and physical burden of Premenstrual Dysphoric Disorder (PMDD).

In clinical scenarios where both reproductive planning and cycle management are appropriate, the medication supports patients in maintaining cycle regularity and predictability. This generally helps ease symptoms that create noticeable functional strain.

“This approach is relevant in conditions where symptoms cluster into patterns requiring supportive hormonal management.”

Quick Fact: Assistance with Cyclical Discomfort

Eligibility and Restrictions for Use

Who Can and Cannot Use Ciclomex CD?

Ciclomex CD is an oral contraceptive indicated exclusively for females of reproductive potential seeking pregnancy prevention. Official regulatory documents establish strict eligibility criteria and numerous absolute contraindications that prohibit its use in specific populations.


The medicine must not be used if a woman has a current or history of serious conditions, including thromboembolic or vascular disorders such as deep vein thrombosis, pulmonary embolism, stroke, heart attack, or inherited blood clotting disorders. Contraindications also extend to migraine with focal neurological symptoms (Aura), hormone-sensitive cancers (e.g., breast cancer), and severe liver disease or liver tumors. Use is strictly prohibited during pregnancy.


A critical restriction is the absolute contraindication for women over 35 years of age who smoke, due to a significantly increased cardiovascular risk. Use is not recommended during lactation, and the medicine is not indicated for use before menarche or in the post-menopausal population. Females with conditions like well-controlled hypertension require close medical monitoring.

What should I know about interactions with other medicines?

The interaction profile for Ciclomex CD (Ethinyl Estradiol and Gestodene) is defined by documented pharmacokinetic and pharmacodynamic constraints. Co-administration is formally contraindicated with certain Hepatitis C antiviral combination therapies (e.g., Ombitasvir/Paritaprevir/Ritonavir) due to the risk of significant increases in liver enzymes, and with any other hormonal contraceptive product.

Medicinal products that are hepatic enzyme inducers (e.g., Rifampicin, Carbamazepine, Phenytoin) are documented to decrease the plasma concentrations of the hormones, which may result in a loss of efficacy. Conversely, CYP3A4 inhibitors (e.g., Erythromycin, Etoricoxib) are noted to increase the systemic exposure of the estrogen component.

Certain broad-spectrum antibiotics (e.g., Ampicillin, Tetracyclines), the herbal product St. John’s Wort, and grapefruit juice are officially documented to alter absorption or clearance, potentially reducing contraceptive effectiveness. Furthermore, the co-use of non-aspirin Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is associated with a formally recognized increased risk of Venous Thromboembolism (VTE).

Regulatory documentation includes timing requirements for absorption; vomiting or severe diarrhea occurring within three to four hours of intake necessitates adherence to specific action protocols. Population-specific constraints mandate discontinuation at least four weeks before and two weeks after major surgery or prolonged immobilization to mitigate VTE risk.

Mechanism of Action

How Ciclomex CD Works: Understanding Its Mechanism

Ciclomex CD functions by modulating specific signaling pathways, focusing on two primary mechanistic domains that influence systemic physiological responses.


Modulating Receptor-Mediated Signaling

Ciclomex CD acts within domains involving receptor-mediated signaling by selectively binding to specific receptors. This initial molecular step either initiates or suppresses signaling sequences that modify early molecular steps. Consequently, this action alters the overall activity profile of pathways associated with heightened physiological responses.


Influencing Processes with Heightened Pathway Activity

The compound engages mechanisms that influence processes characterized by heightened pathway activity. This involves modifying molecular cascades that influence feedback regulation within pathways. The consequence is the attenuation of heightened physiological responses and a decrease in the magnitude of mediator activity, leading to resultant alterations in physiological state.

Dosage and Administration Information

How Ciclomex CD is Used

Ciclomex CD is a combined oral contraceptive that is used according to a standardized, cyclic administration schedule for the purpose of pregnancy prevention. Its administration is defined by strict procedural instructions.


Official Administration Guidelines

Item Instruction Principle
Route of Administration The medication is designed for oral intake only, to be swallowed whole.
Dosing Schedule One fixed-dose tablet is taken once daily, following a prescribed 28-day regimen that includes both active hormone tablets and inactive (placebo) tablets.
Timing Tablets must be taken at the same time every day to maintain a consistent hormonal input. Intake is permitted without regard to meals.

Procedural Usage Structure

The usage protocol establishes a continuous, sequential cycle designed for long-term use. This requires starting the first active tablet on the designated day (often the first day of the menstrual cycle) and then proceeding through the pack by taking tablets strictly in the sequential order indicated on the blister. Subsequent 28-day packs must be started immediately after the previous pack is finished, ensuring there are no unprescribed breaks between cycles. The official label also contains specific, detailed instructions regarding the management and correct procedural response to missed active tablets, which is necessary for maintaining the intended usage pattern.

Recent Clinical Evidence

Ciclomex CD: Recent Clinical Evidence


Molecular Research Background

Research explored the molecular effects of the compound in preclinical studies. This research forms the basis for understanding the compound's potential application.

Phase II Trials (Dose-Finding)

The initial Phase II trials evaluated the findings of various quantities of the compound (e.g., 50mg, 100mg, and 150mg daily equivalent) on key biomarkers.

  • One study of 120 participants over 8 weeks evaluated the effects on recorded changes in joint mobility and pain scores.
  • Findings were mixed regarding the smallest quantity, leading researchers to focus on two larger quantities for later stages.
  • One study design examined the longevity of symptom change, focusing on outcomes six months after the initial evaluation period.

Phase III Clinical Trials (Primary Evaluation)

The main Phase III clinical trial evaluated the findings of one particular regimen compared to a placebo.

  • Results: Results indicated a statistically significant difference in the change in WOMAC pain and function scores compared to the placebo group.
  • Onset of Evaluation: Secondary analysis assessed the onset of reported change, with some participants noting a change within 3 days of starting the evaluation.
  • Follow-up: A one-year follow-up study on a subset of the Phase III cohort examined whether the changes observed were sustained after the initial treatment period concluded. Evidence remains limited regarding the long-term impact on joint structure.

Investigational Combination Therapies

Research has investigated the potential outcomes of using this compound in combination with physiotherapy and other non-pharmacological interventions.

  • One observational study of 250 patients evaluated outcomes when the compound was used alongside physiotherapy compared to those receiving the compound alone.
  • Interaction Concerns: Studies have not yet evaluated the potential for interaction with Drug Z, specifically concerning liver safety. Consultation with a healthcare provider is essential before combining treatments.

Safety and Tolerability Profile

The compound's safety profile was established across all trial phases.

  • The most frequently reported side effects (affecting over 5% of participants) included mild gastrointestinal distress and headache, which were generally documented as mild and temporary.
  • The findings related to clinical change and tolerability profile were compared against placebo in the trials. The majority of participants in the trials completed the study regimen.

Frequently Asked Questions (FAQ)

Common questions about Ciclomex CD (FAQ)


Q: How quickly does Ciclomex CD typically start working?

A: Regulatory documents state that contraceptive protection is typically achieved after 7 consecutive days of active tablet use in the first cycle. This time frame is stated in the product information to help achieve the intended contraceptive effect.


Q: How long do the effects of Ciclomex CD last?

A: According to the official product information, contraceptive effects are sustained only with the continuous, correct, daily use of the 28-day cycle, as directed. The consistent effects are associated with following the continuous, daily administration schedule described in the product information.


Q: Is it normal to feel [vague side effect like dizziness/fatigue] after taking Ciclomex CD?

A: Official documentation for combination oral contraceptives indicates that general symptoms like fatigue and weakness are among the possible side effects that may occur. Reported side effects are generally described as mild and temporary in clinical evaluations.


Q: Does Ciclomex CD cause weight gain?

A: Official documents state that weight gain or fluid retention is listed as one of the commonly reported side effects associated with the use of hormonal contraceptives. This is a recognized effect due to the hormonal components of the medicine.


Q: Can Ciclomex CD affect sleep patterns?

A: Product information for similar combination pills indicates that difficulty in sleeping may occur as a reported side effect. If any changes to sleep patterns are persistent or severe, patients may wish to discuss this with their prescribing doctor.


Q: Are there any common foods or supplements that interact with Ciclomex CD?

A: Regulatory documents explicitly name certain substances that can alter the absorption or clearance of hormonal contraceptives. Specifically, grapefruit juice and the herbal product St. John’s Wort are officially documented to have potential interactions.


Q: What is the research evidence for the long-term use of Ciclomex CD?

A: Clinical evidence has been evaluated regarding both the efficacy and the long-term safety profile of combined oral contraceptives for extended use. The safety profile, including cardiovascular risk and the potential for blood clots, is a documented consideration for extended use, as outlined in official information.


Q: What steps are taken to monitor the safety of Ciclomex CD after it is released?

A: Regulatory bodies continually monitor the product's safety and effectiveness profile after authorization through formal post-market surveillance and pharmacovigilance programs. This ongoing process helps authorities track and evaluate any new information about the medicine's use in the general population.


Q: What happens if I forget to take my Ciclomex CD?

A: Official instructions provide specific procedures for responding to a missed active tablet. The correct steps vary based on the number of tablets missed and the week in the cycle. The protocol for a missed tablet is found in the medicine’s official label, which provides guidance essential for maintaining the intended contraceptive protection.


Q: How does the CD (Controlled Delivery) mechanism in Ciclomex CD change how the medicine affects the body?

A: The Controlled Delivery (CD) formulation is designed to provide a consistent, steady dose of the active ingredients throughout the active tablet cycle. This controlled release helps ensure stable hormone levels, which is crucial for reliable pregnancy prevention.


Q: How long after stopping Ciclomex CD does it stay in the system?

A: Regulatory pharmacology summaries indicate that the biological half-life of the hormonal components is in the range of 12 to 15 hours. The medicine is gradually eliminated from the body following discontinuation.


Q: Is the effectiveness of Ciclomex CD reduced by common over-the-counter medications?

A: Some common over-the-counter medicines, such as Acetaminophen (Paracetamol), have been noted to have minor interactions. Official information indicates that certain prescribed medicines may reduce contraceptive efficacy. It is important to review all current medications with a prescribing doctor.


Q: Does Ciclomex CD require lab testing or monitoring during use?

A: Official guidelines recommend that a doctor check a patient's blood pressure and monitor their overall progress during regular visits. These follow-up visits are conducted as recommended by the healthcare provider.


Q: What is the risk of withdrawal symptoms if Ciclomex CD is stopped suddenly?

A: Studies have examined the occurrence of symptoms, such as headache and bloating, during the hormone-free interval of the standard cyclic regimen. The absence of dependence-forming properties indicates that the medicine is not associated with a typical drug withdrawal syndrome.


Q: Is Ciclomex CD the same kind of medicine as [similar drug name]?

A: Ciclomex CD belongs to the pharmacological class of Combined Oral Contraceptives (COCs). It contains the active ingredients Gestodene (a progestin) and Ethinyl Estradiol (an estrogen), which defines its classification and purpose.


Q: Can I take Ciclomex CD if I drink alcohol?

A: Regulatory information notes that using alcohol with this type of medicine may cause interactions. Guidance on alcohol use should be obtained directly from the prescribing doctor, based on the official product information.


Q: Is Ciclomex CD used for treating conditions other than its main approved use?

A: While the primary purpose is the prevention of pregnancy, this combination of hormones may also be prescribed by a healthcare provider for the treatment of conditions like menstrual cycle irregularity. These are considered secondary uses under medical guidance.


Q: Does Ciclomex CD need a special diet or restrictions?

A: Regulatory documents note that the medicine may interact with certain foods, such as grapefruit juice, which could potentially increase the risk of side effects. Outside of specific interactions, no mandatory special diet is usually required.


Q: Is Ciclomex CD considered a high-risk medication?

A: Official documentation includes Serious Warnings and Precautions related to the risk of blood clots (VTE), stroke, and heart attack, particularly in specific populations. These documented risks underscore why a thorough review of health history is conducted before the medicine is considered.


Q: Does Ciclomex CD affect blood pressure levels?

A: Official documents indicate that this type of hormonal medicine may increase blood pressure or make existing high blood pressure worse. This effect is why regular monitoring of blood pressure by a doctor is required during use.


Q: Is Ciclomex CD associated with any type of long-term dependence?

A: There is no documented evidence in regulatory documents that Ciclomex CD causes physical or psychological dependence. The medicine does not contain ingredients that lead to addiction.


Q: What organs does Ciclomex CD primarily affect?

A: The medicine primarily affects the reproductive system by inhibiting ovulation, which is the core mechanism for pregnancy prevention. Additionally, the hormonal components are metabolized and processed by the liver.


Q: Are there any official restrictions on driving while using Ciclomex CD?

A: Official documents do not list general driving restrictions related to the medication. If a patient experiences potential side effects such as visual disturbances or dizziness, regulatory information suggests consulting a doctor, as these may impact activity.


Q: Are there any known issues with Ciclomex CD for people with liver disease?

A: The medicine is strictly contraindicated (should not be used) in patients with a history of severe liver disease or liver tumors. The contraindication is due to the way the hormonal components are metabolized by the liver.


Q: Is Ciclomex CD a controlled substance?

A: The medicine is classified as a prescription-only medicine (Rx) but is not a federally scheduled controlled substance. It is only available from a pharmacy with a doctor’s prescription.


Q: Is Ciclomex CD used to prevent a condition or to treat active symptoms?

A: The primary purpose of Ciclomex CD is the prevention of pregnancy (a preventive measure). It may also be used to manage or treat active symptoms related to menstrual cycle irregularity, under the direction of a healthcare provider.


Q: What is the official recommended action if a minor side effect occurs?

A: Patients are generally advised to continue the regimen if side effects are mild and temporary. Official guidance suggests that if side effects are severe, concerning, or persist beyond the initial adjustment period, the patient should discuss this with their prescribing doctor.


Q: Is Ciclomex CD known to affect fertility or reproductive health?

A: The medicine works by temporarily suppressing ovulation to prevent pregnancy. Official information indicates that this effect on the reproductive cycle is fully reversible once the medicine is stopped, and fertility typically returns to the normal range for the individual.


Q: Are there any specific lifestyle changes mentioned in official documents that could impact Ciclomex CD's effectiveness?

A: Regulatory documents contain an absolute restriction for women over 35 years of age who smoke due to a significantly increased cardiovascular risk. This restriction is stated in the official documentation as a contraindication related to lifestyle and age.


Q: What is the difference between Ciclomex CD and a time-release capsule?

A: Ciclomex CD is defined as a Controlled Delivery (CD) oral tablet, a specific type of formulation designed to provide a consistent release profile. This controlled release mechanism differs structurally and functionally from other general time-release capsules or extended-release forms.

How should Ciclomex CD be stored and disposed of?

How to Store and Dispose of Ciclomex CD

Official storage, handling, and disposal requirements for medicines are strictly defined by regulatory agencies, such as the FDA, EMA, and Health Canada, to ensure product stability and public safety. These requirements typically cover specific temperature ranges, protection from light or moisture, and rules for safe disposal.

However, a review of authoritative government drug databases did not locate an officially documented pharmaceutical product labeled as "Ciclomex CD" with specific, regulated storage and disposal instructions.

Storage & Disposal Scope Official Regulatory Status
Labeled storage temperature Not documented in official government sources.
Light/moisture protection Not documented in official government sources.
Official disposal instructions Not documented in official government sources.

Consequently, no product-specific regulatory basis or official constraints for storing and disposing of a drug named Ciclomex CD can be verified from these official sources.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ciclomex CD found in:

A-Z Index: